Home page > News and press release
 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
 
Chiesi explores the impact of climate change on people living with respiratory...
Chiesi Group proudly shares its contribution to the thought-provoking series “The Climate and Us”, presented by the Global Climate and Health Alliance and produced for them by BBC...
1/22
ARCHIVE NEWS
CHIESI’S SUSTAINABILITY REPORT 2022: A YEAR OF TANGIBLE ACHIEVEMENTS FOR PATIENTS, COMMUNITIES, AND THE PLANET
Chiesi’s 2022 Sustainability Report: “Purpose First”
Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
2022 for Chiesi: The Group’s international growth continues
Skupina Chiesi in družba Affibody sodelujeta pri razvoju in trženju inovativnih oblik zdravljenja bolezni dihal
Chiesi Group stands in solidarity with the people of #Turkiye and #Syria
Chiesi appoints Giuseppe Accogli as new Group CEO
The Chiesi Group has undergone B Corp re-certification and set itself new, even more demanding operational goals until 2025
The Chiesi Group monitors the implementation of measures for a healthier and more sustainable future
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
RARE IS NOT SO RARE: #WEWEARSTRIPES CAMPAIGN 2022 LAUNCHED TO MARK RARE DISEASE DAY
Helping the World to Breathe - Chiesi Group among the protagonist of the ATS docuseries
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID- 19 pandemic
Chiesi Group Announces Establishment of New Global Rare Diseases Division